Why Seagen is poised to stretch its lead in the expanding ADC landscape

There’s a growing understanding that all antibody-drug conjugate technologies — even among the first-generation platforms — are not created equal, but acquisition target Seagen has a pipeline strategy that could deliver new commercial opportunity, regardless of whether its technology remains on top.

Seagen Inc. (NASDAQ:SGEN), a pioneer in ADCs, is building a pipeline almost entirely around first-in-class targets that face little near-term competition, even as the broader industry’s pipeline of ADCs continues to grow...